NAD+ vs Epithalon

Same theme, different machinery

Longevity research is a broad church, and NAD+ and Epithalon show just how broad. Both are studied under the "ageing" banner, but they belong to entirely different molecular categories and are thought to act through entirely different pathways. NAD+ is a small-molecule coenzyme — a piece of core metabolic hardware present in every cell. Epithalon is a synthetic peptide, a short chain of amino acids modelled on a natural pineal-gland extract. One is a cofactor the cell cannot run without; the other is a signalling molecule proposed to switch specific programmes back on. Putting them side by side is less "which is better" than "which question are you asking" — and the table below makes the split concrete.

NAD+: the metabolic coenzyme

NAD+ (Nicotinamide Adenine Dinucleotide) is a pyridine dinucleotide coenzyme with a molecular weight of roughly 663 Da — a small molecule, not a peptide. It plays two distinct roles in the cell. As a redox cofactor it cycles between NAD+ and NADH across glycolysis, the TCA cycle and the mitochondrial electron transport chain, making it a rate-limiting component of ATP production. As a co-substrate it is consumed — not recycled — by three families of enzymes: the sirtuin deacetylases (SIRT1-7) that regulate metabolic gene expression and mitochondrial biogenesis, the PARPs that signal and repair DNA damage, and the CD38 ectoenzyme involved in calcium signalling.

The reason NAD+ features so heavily in longevity research is that intracellular NAD+ pools decline substantially with age across human tissues including muscle, liver and brain, with rising CD38 expression identified as a dominant driver of that decline. That observation is the central rationale for NAD+-restoration research — whether by direct administration, dosing of precursors such as NMN and NR, or upstream enzyme inhibition. Crucially, the NAD+ evidence base is broad and drawn from multiple independent laboratories, which places it on firmer preclinical footing than many peptide candidates. Researchers sourcing material can buy NAD+ UK as a ≥99%-purity reagent with a COA for in vitro work.

Epithalon: the telomere tetrapeptide

Epithalon (also written Epitalon) is a synthetic tetrapeptide — the sequence Ala-Glu-Asp-Gly, abbreviated AEDG — derived from epithalamin, a natural polypeptide extract of the pineal gland. It was developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology and is one of the most-studied peptides in telomere biology. Its headline proposed mechanism is telomerase activation: telomeres are the protective caps at the ends of chromosomes that shorten with each cell division, and telomerase is the enzyme that can rebuild them — an activity largely absent in most somatic cells. Khavinson's group has published work claiming Epithalon reactivates this enzyme and extends telomere length.

Beyond telomeres, Epithalon is studied for an epigenetic mode of action — a 2020 Molecules paper proposed histone modification and gene-regulatory-element activation to explain effects on neurogenesis-related gene expression — and for its pineal heritage, which ties it to melatonin regulation and circadian rhythm research. The important caveat is evidential: much of the telomerase and epigenetic data originates with the peptide's developers, and independent replication in peer-reviewed Western journals remains limited. The full mechanistic detail sits on our Epithalon knowledgebase page, and researchers can buy Epithalon UK as a research-grade reagent.

What the differences mean in a research context

The cleanest way to hold these two apart is by category. NAD+ is infrastructure: a coenzyme the cell already runs on, whose age-related depletion is well documented and whose restoration is being probed as a way to keep sirtuin- and PARP-dependent programmes running. Epithalon is a signal: a designed peptide proposed to switch a specific, normally-silent programme — telomerase — back on, with additional circadian and epigenetic threads attached. A researcher interested in cellular bioenergetics, redox balance or sirtuin activity is working in NAD+ territory; one interested in telomere length, replicative senescence or pineal-circadian biology is working in Epithalon territory.

Their structures reinforce the divide. NAD+ is a small dinucleotide with a defined molecular weight and a long biochemical pedigree; its handling note in the lab is simply that it is hygroscopic and best used promptly after reconstitution. Epithalon is a four-residue peptide whose interest lies in a proposed gene-regulatory action rather than a metabolic one. Neither source page assigns Epithalon a defined half-life, so any duration comparison stays qualitative — but the more meaningful contrast is mechanistic, not pharmacokinetic.

Evidence weighting matters too. The NAD+-decline literature spans several independent groups and multiple tissues, whereas Epithalon's central telomerase claims lean heavily on its originating laboratory. That does not make Epithalon uninteresting — it makes it a compound where independent in vitro replication is exactly the kind of work still worth doing. In practice the two are studied by different sub-fields, and it is common to see NAD+ paired with other mitochondrial-support research compounds rather than with a telomere peptide.

The bottom line

NAD+ and Epithalon share a longevity headline and almost nothing else. NAD+ is a metabolic coenzyme with a broad, independently-replicated preclinical base, central to energy metabolism and sirtuin/DNA-repair signalling. Epithalon is a pineal-derived tetrapeptide studied for a proposed telomerase and epigenetic mechanism, with a narrower and more developer-dependent evidence trail. They answer different research questions and are not substitutes for one another. For research-grade material, see our dedicated pages to buy NAD+ UK and buy Epithalon UK, each ≥99% purity with a COA and supplied strictly for in vitro use.